A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
| Autor: | Scagliotti, Giorgio, Moro-Sibilot, Denis, Kollmeier, Jens, Favaretto, Adolfo, Cho, Eun Kyung, Grosch, Heidrun, Kimmich, Martin, Girard, Nicolas, Tsai, Chun-Ming, Hsia, Te-Chun, Brighenti, Matteo, Schumann, Christian, Wang, Xuejing Aimee, Wijayawardana, Sameera R., Gruver, Aaron M., Wallin, Johan, Mansouri, Kambiz, Wacheck, Volker, Chang, Gee-Chen |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology January 2020 15(1):80-90 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|